Home / Stocks / ALNY

Alnylam Pharmaceuticals (ALNY, Biotechnology) Stock Valuation & Fair Value Quality business with a solid forward outlook

Alnylam Pharmaceuticals (ALNY, Biotechnology) trades at a blended P/E of 46.4, about 73% below its historical normal valuation, with a forward growth estimate of 49.1% and a PEG of 0.94. Analysts' one-year estimates have been hit 27% of the time. Priced at its historical normal P/E of 170.7 on the same blended earnings, the 2026-09-18 close of $239.56 corresponds to about $882 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
46.4
Normal P/E
170.7
PEG
0.94
Fwd growth
49.1%
Div yield
0.0%
RSI (14)
50.3
Neutral
Technical context
  • Price $246.51 at the 2026-09-23 close, 0.5% below the 20-day average ($247.77) and 0.2% above the 50-day ($246.02).
  • RSI (14) at 50.3.
  • 52-week range $205.48 to $491.22: the price is 49.8% below the high and 20.0% above the low.

The Street vs SeerForecast

Wall Street's mean price target for ALNY is $371.35 across 26 analysts, 50.6% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: quality business with a solid forward outlook. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been quality business with a solid forward outlook since 2026-07-25.

Blended P/E and rating by weekBlended P/E moved from 54.6 to 46.4 between 2026-07-25 and 2026-09-21, against a normal P/E of 170.7, with 0 rating changes over 20 recorded weeks.2026-07-25: P/E 54.6, Quality business with a solid forward outlook (recalculated)2026-07-27: P/E 54.6, Quality business with a solid forward outlook (recalculated)2026-07-31: P/E 54.6, Quality business with a solid forward outlook (recalculated)2026-08-03: P/E 43.4, Quality business with a solid forward outlook2026-08-07: P/E 43.4, Quality business with a solid forward outlook (recalculated)2026-08-10: P/E 46.0, Quality business with a solid forward outlook2026-08-14: P/E 46.0, Quality business with a solid forward outlook (recalculated)2026-08-17: P/E 47.3, Quality business with a solid forward outlook2026-08-21: P/E 47.3, Quality business with a solid forward outlook (recalculated)2026-08-24: P/E 48.3, Quality business with a solid forward outlook2026-08-27: P/E 48.3, Quality business with a solid forward outlook (recalculated)2026-08-28: P/E 48.3, Quality business with a solid forward outlook (recalculated)2026-08-30: P/E 48.3, Quality business with a solid forward outlook (recalculated)2026-08-31: P/E 47.7, Quality business with a solid forward outlook2026-09-05: P/E 47.7, Quality business with a solid forward outlook (recalculated)2026-09-07: P/E 52.5, Quality business with a solid forward outlook2026-09-12: P/E 52.5, Quality business with a solid forward outlook (recalculated)2026-09-14: P/E 48.8, Quality business with a solid forward outlook2026-09-19: P/E 48.8, Quality business with a solid forward outlook (recalculated)2026-09-21: P/E 46.4, Quality business with a solid forward outlook50.0100.0150.0Jul 25Aug 8Aug 23Sep 7Sep 21Normal P/E 170.7
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-25P/E 54.6-68%Quality business with a solid forward outlook
2026-08-03P/E 43.4-75%Quality business with a solid forward outlook
2026-09-21P/E 46.4-73%Quality business with a solid forward outlook ← now

Frequently asked questions

Is Alnylam Pharmaceuticals stock overvalued?

At a blended P/E of 46.4 versus its historical normal P/E of 170.7, Alnylam Pharmaceuticals trades about 73% below its typical valuation, with a PEG of 0.94 on 49.1% forward growth. tickerseer currently rates it quality business with a solid forward outlook.

What is Alnylam Pharmaceuticals's fair value and PEG?

Alnylam Pharmaceuticals trades at a blended P/E of 46.4 against a historical normal P/E of 170.7, a PEG of 0.94, and a forward growth estimate of 49.1%. Priced at its historical normal P/E of 170.7 on the same blended earnings, the 2026-09-18 close of $239.56 corresponds to about $882 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Alnylam Pharmaceuticals changed?

tickerseer's rating has been quality business with a solid forward outlook since 2026-07-25.

What is the analyst price target for Alnylam Pharmaceuticals?

The mean Wall Street price target for Alnylam Pharmaceuticals is $371.35 across 26 analysts, 50.6% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track ALNY free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.